Stay updated with breaking news from Spiriva. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharmaceutical companies have strategically increased their presence in chronic therapies, focused on new product launches, and ventured into new therapies to capitalise on market opportunities. ....
Aside from expensive valuations, the Street remains bullish on the growth prospects for Lupin, especially after the approval of its blockbuster inhalation drug, the generic of Spiriva. ....
The growing positivity around Lupin is clearly demonstrated in the stock’s performance, which has spiked over 38 percent since the start of April. However, some analysts believe the valuation is a bit stretched. ....